# Gemeinsamer Bundesausschuss / IQWiG

Source: https://onco.cc/institutions/g-ba-iqwig/  
OnCo record `g-ba-iqwig` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Germany's decision-making body for what statutory insurance covers (G-BA) and the institute that assesses added benefit of new drugs (IQWiG), which together set cancer drug prices under the AMNOG process.

## Summary

The Gemeinsamer Bundesausschuss is the self-governing body of insurers, physicians and hospitals that determines the benefits covered by Germany's statutory health insurance, and the Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen in Cologne is the independent institute it commissions to assess evidence. Under the AMNOG early benefit assessment since 2011, every new drug is judged for added benefit against the appropriate comparator within a year of launch, and the rating (from major added benefit to none) drives the price negotiated with the insurers' association. IQWiG's demanding view of surrogate endpoints, single-arm trials and quality-of-life data has shaped how companies design oncology trials for Europe, and G-BA decisions also govern screening programmes and quality requirements for cancer centres.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: G-BA; Federal Joint Committee; IQWiG; Institute for Quality and Efficiency in Health Care
- City: Berlin, DE
- Type: government
- Website: https://www.g-ba.de

## Sources

- G-BA: https://www.g-ba.de
- IQWiG: https://www.iqwig.de

## Connected records

- institutions: [Bundesinstitut für Arzneimittel und Medizinprodukte](https://onco.cc/institutions/bfarm/), [Deutsche Krebsgesellschaft](https://onco.cc/institutions/deutsche-krebsgesellschaft/), [Deutsche Krebshilfe](https://onco.cc/institutions/deutsche-krebshilfe/), [European Medicines Agency](https://onco.cc/institutions/ema/), [German Cancer Research Center (DKFZ)](https://onco.cc/institutions/dkfz/), [Haute Autorité de Santé](https://onco.cc/institutions/has-france/), [ISPOR (The Professional Society for Health Economics and Outcomes Research)](https://onco.cc/institutions/ispor/), [National Institute for Health and Care Excellence](https://onco.cc/institutions/nice/), [Paul-Ehrlich-Institut](https://onco.cc/institutions/paul-ehrlich-institut/), [Zentrum für Krebsregisterdaten am Robert Koch-Institut](https://onco.cc/institutions/zfkd-rki/)
- terms: [AMNOG (Germany, 2011)](https://onco.cc/terms/amnog/), [EU HTA Regulation (EU) 2021/2282: joint clinical assessments](https://onco.cc/terms/eu-hta-regulation/), [Hazard ratio (HR)](https://onco.cc/terms/hazard-ratio/), [Overall survival (OS)](https://onco.cc/terms/os/), [Progression-free survival (PFS)](https://onco.cc/terms/pfs/), [Real-world evidence](https://onco.cc/terms/real-world-evidence/)
- people: [Sonja Optendrenk](https://onco.cc/people/sonja-optendrenk/), [Thomas Kaiser](https://onco.cc/people/thomas-kaiser/)
- bottlenecks: [Biomarkers are not validated or standardised](https://onco.cc/bottlenecks/b-biomarker-validation/), [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/)
- ideas: [Copy the Cancer Drugs Fund: pay for uncertain drugs while collecting the data](https://onco.cc/ideas/idea-cost-managed-access-everywhere/)

---
JSON: https://onco.cc/api/v1/entities/g-ba-iqwig.json